DXCM vs INO · P/E 63, rev $2.50B vs $88.0M cap
DexCom Inc (DXCM) versus Inovio Pharmaceuticals Inc (INO) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Inovio Pharmaceuticals Inc (INO) is a biotechnology company listed on US.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported INO revenue for 2026-06-30 was $0. Net income was -$6.0M. INO currently screens at market cap $88.0M.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. INO currently screens at market cap $88.0M.
Not investment advice. Open the DXCM and INO stock pages for the full models.
Not investment advice.